期刊
BRAIN RESEARCH
卷 914, 期 1-2, 页码 48-56出版社
ELSEVIER
DOI: 10.1016/S0006-8993(01)02772-X
关键词
Alzheimer's disease; Lewy body; neurodegeneration; Parkinson's disease; synuclein
资金
- NIA NIH HHS [AG5131, AG10869, AG18440, AG10124, AG092215] Funding Source: Medline
The main objective of this study was to determine if levels of alpha-, beta- and/or gamma -synuclein mRNAs are differentially affected in brains of Lewy body disease (LBD) and Alzheimer's disease (AD) patients, compared to controls. In control cases, highest levels of expression were observed in the neocortex and the lowest in basal ganglia and substantia nigra. beta -Synuclein was the most abundant message (75-80%), followed by gamma -synuclein (10-15%) and alpha -synuclein (8-10%). Analysis of the superior temporal cortex, a region selectively affected in LBD and AD, showed that compared to controls, levels of a-synuclein were increased in cases of diffuse LBD (DLBD), levels of beta -synuclein were decreased in AD and DLBD, and levels of gamma -synuclein were increased in AD cases. This study suggests that a critical balance among products of the synuclein gene is important to maintain normal brain function and that alterations in this balance might be associated with neurodegenerative disorders. (C) 2001 Elsevier Science BY All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据